Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer

Prostate cancer therapies against androgen receptor (AR) eventually develop lethal resistance; thus, exploring new therapeutic approaches is urgent for prostate cancer treatment. Acetyltransferase p300/CBP are key coactivators for AR-mediated transcription and represent promising therapeutic targets to inhibit AR activity in prostate cancer. We describe the design synthesis and evaluation of a new class of p300/CBP PROTAC degraders. We identified an excellent p300/CBP degrader <b>MJP6412</b>, which effectively induced degradation of p300/CBP proteins, downregulated AR target genes, and inhibited cell growth of human prostate cancer cell lines and enzalutamide-resistant cells with IC<sub>50</sub> even at nanomolar concentrations. Furthermore, <b>MJP6412</b> demonstrated significant inhibition of tumor growth in a VCaP xenograft model. Collectively, <b>MJP6412</b> is a promising lead compound for the treatment of prostate cancer, especially enzalutamide-resistant prostate cancer.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2024-09-30
DOI
https://doi.org/10.1021/acs.jmedchem.4c01100
Citations
11
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
2.57

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer

Shumin Ma, Chong Qin, Mengyao Li, Xiaoyu Chen et al.
11 citations
Journal of Medicinal Chemistry
Protein Degradation and Inhibitors
2.57
article

Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer

Shumin Ma, Chong Qin, Mengyao Li, Xiaoyu Chen, Siqi Zhang, Chengwei Zhang, Penghui Lu, Zixuan Yang, Mengjun Ma, Shuangshuang Nie
article en
11 citations

Abstract

Prostate cancer therapies against androgen receptor (AR) eventually develop lethal resistance; thus, exploring new therapeutic approaches is urgent for prostate cancer treatment. Acetyltransferase p300/CBP are key coactivators for AR-mediated transcription and represent promising therapeutic targets to inhibit AR activity in prostate cancer. We describe the design synthesis and evaluation of a new class of p300/CBP PROTAC degraders. We identified an excellent p300/CBP degrader <b>MJP6412</b>, which effectively induced degradation of p300/CBP proteins, downregulated AR target genes, and inhibited cell growth of human prostate cancer cell lines and enzalutamide-resistant cells with IC<sub>50</sub> even at nanomolar concentrations. Furthermore, <b>MJP6412</b> demonstrated significant inhibition of tumor growth in a VCaP xenograft model. Collectively, <b>MJP6412</b> is a promising lead compound for the treatment of prostate cancer, especially enzalutamide-resistant prostate cancer.

Journal of Medicinal ChemistryVol. 67(19)
Qingdao National Laboratory for Marine Science and Technology (CN), Ocean University of China (CN)
Taishan Scholar Project of Shandong Province, Key Technology Research and Development Program of Shandong, Natural Science Fund for Distinguished Young Scholars of Shandong Province
Good health and well-being
Openalex Percentile: Top 10%
Protein Degradation and Inhibitors
2.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.